CLEVELAND and NEW ORLEANS, Feb. 3, 2012 (GLOBE NEWSWIRE) -- Medical researchers from The University of Texas Health Science Center at Houston (UTHealth) Medical School presented new research results this morning at the American Heart Association International Stroke Conference that highlight the role of the spleen in the mechanisms underlying how MultiStem®, a novel allogenic stem cell therapy being developed by Athersys, Inc. (Nasdaq:ATHX), reduces damage and enhances functional recovery in animals after an ischemic stroke.
